Compare Global X Defense Tech ETF (SHLD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Tango Therapeutics Inc. — how do they compare? Global X Defense Tech ETF trades at $59.75 (market cap $6.34B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Global X Defense Tech ETF is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Defense Tech ETF for 45 Days and Tango Therapeutics Inc. for 0 Days on average.
| SHLD | TNGX | |
|---|---|---|
Market Cap | $6.34B | $3.75B |
Volume | 1,202,620 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $32.90 |
52-Week Low | $58.20 | $7.50 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $59.34, down 0.82% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF focuses on defense technology and cybersecurity with global diversification beyond U.S. names. Recent institutional buying includes Focus Financial Network increasing its stake by 55.4% in Q2 2026 (SEC filing, August 2026) and Balefire LLC's new $1.12 million position.
Geopolitical tensions and rising global defense budgets support long-term growth potential, though the ETF faces competition from broader aerospace funds and sensitivity to defense policy changes. The current technical weakness near support at $58-59 presents a potential entry point for investors bullish on defense tech innovation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
